by Extivita | Feb 6, 2008 | Chronic Heart Failure
Abstract: The current use of doxorubicin is regarded as an absolute contraindication for hyperbaric oxygen (HBO2) therapy because of the increased risk of cardiotoxicity. The aim of this study was to investigate whether additional exposure to HBO2 during the course of...
by Extivita | Jan 23, 2003 | Sarcoma
Abstract: The objectives of the study were to test the hypothesis that hyperbaric levels of oxygen enhance the sensitivity of a sarcoma cell line to doxorubicin (Adriamycin) both in vitro and in vivo in a rat model of pulmonary metastases and to test the feasibility...
by Extivita | May 6, 1998 | Cancer
Abstract: Currently, advanced prostate cancer (CaP) is not curable. In this report hyperbaric oxygen (HBO) is examined as an adjuvant to chemotherapy and as a stand-alone treatment. CaP cell monolayers grown under normoxic conditions were exposed to cisplatin, taxol...
by Extivita | Jan 1, 1988 | Cancer
Abstract: Two series of experiments were conducted to ascertain whether hyperbaric oxygenation (HBO) treatment with or without antineoplastic chemotherapy can really suppress tumor development in N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN)-induced bladder tumor in...
by Extivita | Feb 1, 1979 | Lymphoma
Abstract: The effects of hyperbaric oxygen (HPO) exposure on the cytotoxicity of Adriamycin (ADM) and nitrogen mustard have been examined in Burkitt’s lymphoma cells (P3J) in vitro. Exposure of cells to 3 atmospheres of pressure HPO for 2 hr produces inhibition...
